On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor antibody screen on the Ortho Clinical Diagnostics VISION Analyzer. This instrumentation change was necessary as Ortho Clinical Diagnostics will be discontinuing support of the existing ProVue instrumentation in the future.
We will notify you of the transition date of our other four laboratories. To read more about this change, click here: Communications
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization